RESUMEN

Methotrexate is used to treat autoimmune and oncologic diseases in children with Down syndrome. However, increased methotrexate-related toxicity is reported in this population. We evaluated differences in the concentrations and distribution of erythrocyte folates in children with Down syndrome as a potential basis for this enhanced toxicity.

Asunto(s)

Síndrome de Down/sangre , Ácido Fólico/sangre , Homeostasis , Preescolar , Eritrocitos/metabolismo , Ácido Fólico/administración & dosificación , Humanos , Metotrexato/farmacología , Metotrexato/toxicidad , Proyectos Piloto , Muestreo , Complejo Vitamínico B/administración & dosificación